Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

Michael P. Lux; Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Wolfgang Janni; Isabell Witzel; Christoph Thomssen; Milena Beierlein; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Bahriye Aktas; Maggie Banys-Paluchowski; Cornelia Kolberg-Liedtke; Achim Wöckel; Hans Christian Kolberg; Nadia Harbeck; Rupert Bartsch; Andreas Schneeweiss; Johannes Ettl; Rachel Würstlein; David Krug; Florin Andrei Taran; Diana Lüftner; Elmar Stickeler

doi:10.1055/a-2074-0125

Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

Michael P. Lux, Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching^*, Wolfgang Janni, Isabell Witzel, Christoph Thomssen, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Achim WöckelHans Christian Kolberg, Nadia Harbeck, Rupert Bartsch, Andreas Schneeweiss, Johannes Ettl, Rachel Würstlein, David Krug, Florin Andrei Taran, Diana Lüftner, Elmar Stickeler

^*Corresponding author for this work

6 Citations (Scopus)

Abstract

In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

Original language	English
Journal	Geburtshilfe und Frauenheilkunde
Volume	83
Issue number	6
Pages (from-to)	664-672
Number of pages	9
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-2074-0125
Publication status	Published - 13.04.2023

Funding

This paper was partly developed as a result of funding from the companies onkowissen.de, Gilead, Lilly, Novartis, Pfizer, and MSD. None of the companies had any part in the preparation and recommendations of this manuscript. The authors are solely responsible for the content of the manuscript.

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)
Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

2.22-21 Gynaecology and Obstetrics
2.22-14 Hematology, Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/a-2074-0125

Cite this

Lux, M. P., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Witzel, I., Thomssen, C., Beierlein, M., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Aktas, B., Banys-Paluchowski, M., Kolberg-Liedtke, C., ... Stickeler, E. (2023). Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 83(6), 664-672. https://doi.org/10.1055/a-2074-0125

@article{a0f9931ebfc842df81e72f1a0758a53d,

title = "Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer",

abstract = "In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.",

author = "Lux, \{Michael P.\} and Hartkopf, \{Andreas D.\} and Fehm, \{Tanja N.\} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, \{Peter A.\} and Wolfgang Janni and Isabell Witzel and Christoph Thomssen and Milena Beierlein and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Bahriye Aktas and Maggie Banys-Paluchowski and Cornelia Kolberg-Liedtke and Achim W{\"o}ckel and Kolberg, \{Hans Christian\} and Nadia Harbeck and Rupert Bartsch and Andreas Schneeweiss and Johannes Ettl and Rachel W{\"u}rstlein and David Krug and Taran, \{Florin Andrei\} and Diana L{\"u}ftner and Elmar Stickeler",

year = "2023",

month = apr,

day = "13",

doi = "10.1055/a-2074-0125",

language = "English",

volume = "83",

pages = "664--672",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "6",

}

Lux, MP, Hartkopf, AD, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Janni, W, Witzel, I, Thomssen, C, Beierlein, M, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Aktas, B, Banys-Paluchowski, M, Kolberg-Liedtke, C, Wöckel, A, Kolberg, HC, Harbeck, N, Bartsch, R, Schneeweiss, A, Ettl, J, Würstlein, R, Krug, D, Taran, FA, Lüftner, D & Stickeler, E 2023, 'Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, vol. 83, no. 6, pp. 664-672. https://doi.org/10.1055/a-2074-0125

TY - JOUR

T1 - Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

AU - Lux, Michael P.

AU - Hartkopf, Andreas D.

AU - Fehm, Tanja N.

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A.

AU - Janni, Wolfgang

AU - Witzel, Isabell

AU - Thomssen, Christoph

AU - Beierlein, Milena

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Kolberg-Liedtke, Cornelia

AU - Wöckel, Achim

AU - Kolberg, Hans Christian

AU - Harbeck, Nadia

AU - Bartsch, Rupert

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Würstlein, Rachel

AU - Krug, David

AU - Taran, Florin Andrei

AU - Lüftner, Diana

AU - Stickeler, Elmar

PY - 2023/4/13

Y1 - 2023/4/13

N2 - In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

AB - In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

UR - https://www.scopus.com/pages/publications/85161628200

U2 - 10.1055/a-2074-0125

DO - 10.1055/a-2074-0125

M3 - Scientific review articles

AN - SCOPUS:85161628200

SN - 0016-5751

VL - 83

SP - 664

EP - 672

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 6

ER -

Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

Abstract

Funding

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this